Use of Ultrasensitive RNA In Situ Hybridization for Determining Clonality in Cutaneous B-Cell Lymphomas and Lymphoid Hyperplasia Decreases Subsequent Use of Molecular Testing and Is Cost-effective
- 24 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (7) , 956-962
Abstract
Primary cutaneous B-cell lymphomas (PCBCLs) are diagnostically challenging entities due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations. Traditional methods for evaluating clonality such as immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) are limited by low sensitivity, which leads to additional costly and time-consuming molecular clonality assays. More recent technology has introduced ultrasensitive bright-field RNA in situ hybridization (BRISH) to the field, which can detect single molecules of light-chain mRNA. The current study evaluated 274 cases of PCBCL in addition to atypical and reactive lymphoid infiltrates, with CISH or BRISH performed on 180 (65.7%). CISH was performed on 105 (58.3%), and BRISH was performed on 75 (41.7%). Significantly fewer immunoglobulin heavy-chain (IGH) rearrangement studies were performed on cases that were evaluated with BRISH as compared with CISH (P=0.02). Subgroup analysis demonstrated that cases with restriction by BRISH were significantly less likely to have subsequent IGH studies performed (P=0.01). The expected costs of cases using CISH versus BRISH were $1053.89 versus $810.32 to the patient and $245.63 versus $225.23 to the laboratory. The use of ultrasensitive BRISH to evaluate clonality in PCBCL reduced the use of IGH rearrangement studies when compared with CISH. In particular, cases with light-chain restriction by BRISH did not result in confirmatory molecular testing. Despite slightly higher costs to the laboratory to perform BRISH, routine use of this methodology can result in cost savings to both the patient and laboratory by decreasing the use of expensive molecular methods.Keywords
This publication has 18 references indexed in Scilit:
- Clonality Assessment of Cutaneous B-Cell Lymphoid ProliferationsThe American Journal of Dermatopathology, 2014
- Dual-Color Ultrasensitive Bright-Field RNA In Situ Hybridization with RNAscope2014
- Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomasDiagnostic Pathology, 2014
- Ultrasensitive RNA In Situ Hybridization for Detection of Restricted Clonal Expression of Low-Abundance Immunoglobulin Light Chain mRNA in B-Cell Lymphoproliferative DisordersAmerican Journal of Clinical Pathology, 2013
- Primary cutaneous B-cell lymphomasJournal of the American Academy of Dermatology, 2013
- Immunoglobulin Light Chain Immunohistochemistry Revisited, With Emphasis on Reactive Follicular Hyperplasia Versus Follicular LymphomaApplied Immunohistochemistry & Molecular Morphology, 2010
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Contribution of Flow Cytometry in the Diagnosis of Cutaneous Lymphoid LesionsJournal of Investigative Dermatology, 2003
- In Situ Hybridization Analysis of Lymphoproliferative DisordersDiagnostic Molecular Pathology, 1994
- Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells.Proceedings of the National Academy of Sciences, 1981